1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis

Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis

  • July 2015
  • -
  • La Merie Publishing
  • -
  • 76 pages

Summary

Table of Contents

Search Inside

Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis


The Competitive Intelligence report Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis describes product portfolios and R&D pipelines of granulocyte colony stimulating factor (G-CSF) and GM-CSF products and product candidates in regulated and in less regulated markets as of July 2015. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.


With 2014 sales of about US$ 6 bln, first and next generation G-CSF products represent an attractive market size for biosimilar proteins in regulated markets. Biosimilar filgrastim products have already been introduced into the the European Union and now are also entering the US market. Importantly, biosimilar products from Indian companies are among the approved products indicating that Indian companies can fulfill Western standards of cGMP manufacturing and cGCP development of at least relatively simple therapeutic proteins such as filgrastim.


The report includes a compilation of currently marketed branded and non-branded G-CSF and GM-CSF products in regulated and less regulated markets for treatment of chemotherapy-induced neutropenia. The report includes the market size of branded G-CSF products in 2014. In addition, the report lists company-specific product portfolios and R&D pipelines of G-CSF/GM-CSF products and projects. Competitor projects are listed in a tabular format providing information on:



  • Drug Codes,

  • Target / Mechanism of Action,

  • Class of Compound,

  • Company,

  • Product Category,

  • Indication,

  • R&D Stage and

  • additional comments with a hyperlink leading to the source of information.


About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Biosimilars Market by Product, Manufacturing, Application - Global Forecast to 2021

Biosimilars Market by Product, Manufacturing, Application - Global Forecast to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

Biosimilars Market by Product (Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing (In-House, CM0) & Application ...

Global Biosimilar Drugs Market Analysis 2016 - Forecast to 2022

Global Biosimilar Drugs Market Analysis 2016 - Forecast to 2022

  • $ 4550
  • Industry report
  • January 2017
  • by Hoovers Research

Hoovers Research analysis is one of the most accurate studies performed using the combinational analytical tools. The report contains up to date financial data derived from varied research sources to present ...

Global Biosimilars Market-Growth, Trends & Forecasts. (2017 - 2022)

Global Biosimilars Market-Growth, Trends & Forecasts. (2017 - 2022)

  • $ 4250
  • Industry report
  • January 2017
  • by Mordor Intelligence LLP

The Global Biosimilars Market was valued at USD 5237.0 currently and is projected to reach USD 28200.0 million by 2020, at a CAGR of 40.3% during the forecast period from 2015 to 2021. The global biosimilars ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.